Key result
Active (oxazolinylphenyl)isoxazoles fit the HRV-14 pore area, while inactive analogs show steric clash.
Why the study?
A model distinguishing active from inactive (oxazolinylphenyl)isoxazoles against HRV-14 based on X-ray crystallography data was needed.
Structural modeling based on X-ray crystallography identifies spatial requirements for (oxazolinylphenyl)isoxazoles to be active against human rhinovirus-14.
Answers are grounded in this paper and cite their sources.
Informs structure-based design of HRV antivirals; leaves open whether optimized compounds will show clinical activity.
A number of (oxazolinylphenyl)isoxazoles have been synthesized and tested against human rhinovirus-14 (HRV-14). Several of the more active compounds have been examined by X-ray crystallography and their orientation in the compound binding site on the capsid protein of HRV-14 has been determined. Based on the minimum inhibitory concentration against HRV-14 and the X-ray conformation of the compounds, a model has been developed which distinguishes between the space-filling properties of the active and inactive compounds in this series. The model was generated by overlaying composite structures and comparing the van der Waals generated volume maps. The results of this study indicate that inactive compounds display areas of excessive bulk particularly around the phenyl ring, while the active compounds occupy space below the pore area of the compound binding site.
No takes yet. Share an insight, caveat, or question.
Diana et al. (1990) studied Human rhinovirus-14 (HRV-14). (oxazolinylphenyl)isoxazoles vs. Inactive compounds was evaluated on Minimum inhibitory concentration against HRV-14 and X-ray conformation. Active (oxazolinylphenyl)isoxazoles occupy space below the pore area of the HRV-14 compound binding site, whereas inactive compounds display areas of excessive bulk around the phenyl ring.
Synapse has enriched 10 related papers. Consider them for comparative context: